95 related articles for article (PubMed ID: 12746736)
1. Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6.
Desai M; Tanus-Santos JE; Li L; Gorski JC; Arefayene M; Liu Y; Desta Z; Flockhart DA
Pharmacogenomics J; 2003; 3(2):105-13. PubMed ID: 12746736
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.
Park JY; Shon JH; Kim KA; Jung HJ; Shim JC; Yoon YR; Cha IJ; Shin JG
J Clin Psychopharmacol; 2006 Apr; 26(2):135-42. PubMed ID: 16633141
[TBL] [Abstract][Full Text] [Related]
4. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study.
Charbit B; Alvarez JC; Dasque E; Abe E; Démolis JL; Funck-Brentano C
Anesthesiology; 2008 Aug; 109(2):206-12. PubMed ID: 18648229
[TBL] [Abstract][Full Text] [Related]
5. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
[TBL] [Abstract][Full Text] [Related]
6. Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers.
Gassó P; Papagianni K; Mas S; de Bobadilla RF; Arnaiz JA; Bernardo M; Lafuente A
Pharmacogenomics; 2013 Oct; 14(13):1551-63. PubMed ID: 24088126
[TBL] [Abstract][Full Text] [Related]
7. QT analysis: a complex answer to a 'simple' problem.
Li L; Desai M; Desta Z; Flockhart D
Stat Med; 2004 Sep; 23(17):2625-43. PubMed ID: 15316947
[TBL] [Abstract][Full Text] [Related]
8. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
Malhotra BK; Glue P; Sweeney K; Anziano R; Mancuso J; Wicker P
Clin Pharmacol Ther; 2007 Mar; 81(3):377-85. PubMed ID: 17339867
[TBL] [Abstract][Full Text] [Related]
9. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).
Desta Z; Kerbusch T; Flockhart DA
Clin Pharmacol Ther; 1999 Jan; 65(1):10-20. PubMed ID: 9951426
[TBL] [Abstract][Full Text] [Related]
10. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype.
Diefenbach K; Jaeger K; Wollny A; Penzel T; Fietze I; Roots I
Sleep Med; 2008 Jul; 9(5):579-82. PubMed ID: 17921051
[TBL] [Abstract][Full Text] [Related]
11. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
[TBL] [Abstract][Full Text] [Related]
12. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.
Novalbos J; López-Rodríguez R; Román M; Gallego-Sandín S; Ochoa D; Abad-Santos F
J Clin Psychopharmacol; 2010 Oct; 30(5):504-11. PubMed ID: 20814331
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses.
Salih IS; Thanacoody RH; McKay GA; Thomas SH
Clin Pharmacol Ther; 2007 Nov; 82(5):548-54. PubMed ID: 17410120
[TBL] [Abstract][Full Text] [Related]
15. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
16. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
17. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
Fliegert F; Kurth B; Göhler K
Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
[TBL] [Abstract][Full Text] [Related]
18. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.
Sowinski KM; Burlew BS
Pharmacotherapy; 1997; 17(6):1305-10. PubMed ID: 9399616
[TBL] [Abstract][Full Text] [Related]
20. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.
Kim KA; Park PW; Liu KH; Kim KB; Lee HJ; Shin JG; Park JY
J Clin Pharmacol; 2008 Jan; 48(1):66-72. PubMed ID: 18094221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
